Cargando…

Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer

Despite enzalutamide's efficacy in delaying the progression of metastatic castration-resistant prostate cancer (CRPC), resistance to this anti-androgen inevitably occurs. Several studies have revealed that the signal transducer and activator of transcription (STAT) 5 plays a role in tumour prog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Erb, Holger H. H., Bodenbender, Julia, Handle, Florian, Diehl, Tamara, Donix, Lukas, Tsaur, Igor, Gleave, Martin, Haferkamp, Axel, Huber, Johannes, Fuessel, Susanne, Juengel, Eva, Culig, Zoran, Thomas, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425943/ https://www.ncbi.nlm.nih.gov/pubmed/32790723 http://dx.doi.org/10.1371/journal.pone.0237248

Ejemplares similares

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
por: Hoefer, Julia, et al.
Publicado: (2016)

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
por: Culig, Zoran
Publicado: (2017)

Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer Cells
por: Vakhrusheva, Olesya, et al.
Publicado: (2022)

Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines
por: Donix, Lukas, et al.
Publicado: (2022)

The stem cell inhibitor salinomycin decreases colony formation potential and tumor‐initiating population in docetaxel‐sensitive and docetaxel‐resistant prostate cancer cells
por: Gruber, Martina, et al.
Publicado: (2019)

Comprehensive Evaluation of Multiple Approaches Targeting ABCB1 to Resensitize Docetaxel-Resistant Prostate Cancer Cell Lines
por: Linke, Dinah, et al.
Publicado: (2022)

PIAS1 is not suitable as a urothelial carcinoma biomarker protein and pharmacological target
por: Erb, Holger Hans Hermann, et al.
Publicado: (2019)

Resistance after Chronic Application of the HDAC-Inhibitor Valproic Acid Is Associated with Elevated Akt Activation in Renal Cell Carcinoma In Vivo
por: Juengel, Eva, et al.
Publicado: (2013)

Mechanisms behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro
por: Juengel, Eva, et al.
Publicado: (2019)

Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro
por: Tsaur, Igor, et al.
Publicado: (2022)

Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib
por: Juengel, Eva, et al.
Publicado: (2015)

IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα(2) through IRF9
por: Erb, Holger H H, et al.
Publicado: (2013)

The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling
por: Nappo, G, et al.
Publicado: (2017)

Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells
por: Makarević, Jasmina, et al.
Publicado: (2014)

Amygdalin Blocks Bladder Cancer Cell Growth In Vitro by Diminishing Cyclin A and cdk2
por: Makarević, Jasmina, et al.
Publicado: (2014)

Amygdalin Influences Bladder Cancer Cell Adhesion and Invasion In Vitro
por: Makarević, Jasmina, et al.
Publicado: (2014)

HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells
por: Juengel, Eva, et al.
Publicado: (2017)

Interleukin‐4 induces a CD44(high)/CD49b(high) PC3 subpopulation with tumor‐initiating characteristics
por: Erb, Holger H.H., et al.
Publicado: (2018)

Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis
por: Wedel, Steffen, et al.
Publicado: (2011)

Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction
por: Zhao, Fuguang, et al.
Publicado: (2020)

Plant-Derived Sulforaphane Suppresses Growth and Proliferation of Drug-Sensitive and Drug-Resistant Bladder Cancer Cell Lines In Vitro
por: Xie, Hui, et al.
Publicado: (2022)

Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways
por: Oh, Su Jung, et al.
Publicado: (2012)

Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients
por: Tsaur, Igor, et al.
Publicado: (2016)

Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro
por: Juengel, Eva, et al.
Publicado: (2016)

Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer
por: Bishop, Jennifer L, et al.
Publicado: (2013)

Impact of primary resistance to front-line targeted therapy in metastatic renal cell carcinoma on subsequent immune-checkpoint-inhibition
por: Börner, J. H., et al.
Publicado: (2023)

Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion
por: Juengel, Eva, et al.
Publicado: (2016)

Correction: Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion
por: Juengel, Eva, et al.
Publicado: (2017)

Shikonin Inhibits Cell Growth of Sunitinib-Resistant Renal Cell Carcinoma by Activating the Necrosome Complex and Inhibiting the AKT/mTOR Signaling Pathway
por: Markowitsch, Sascha D., et al.
Publicado: (2022)

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy
por: Santer, Frédéric R., et al.
Publicado: (2015)

Mistletoe Extracts from Different Host Trees Disparately Inhibit Bladder Cancer Cell Growth and Proliferation
por: Juengel, Eva, et al.
Publicado: (2023)

sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients
por: Tsaur, Igor, et al.
Publicado: (2015)

Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells
por: Tsaur, Igor, et al.
Publicado: (2015)

HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A
por: Juengel, Eva, et al.
Publicado: (2014)

p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer
por: Gruber, Martina, et al.
Publicado: (2020)

Shikonin Reduces Growth of Docetaxel-Resistant Prostate Cancer Cells Mainly through Necroptosis
por: Markowitsch, Sascha D., et al.
Publicado: (2021)

Immunotherapy in prostate cancer: new horizon of hurdles and hopes
por: Tsaur, Igor, et al.
Publicado: (2020)

Correction to: Immunotherapy in prostate cancer: new horizon of hurdles and hopes
por: Tsaur, Igor, et al.
Publicado: (2021)

Pandemic Spread of COVID-19 Mutant Variants Will Facilitate Next-generation Sequencing Capacities for Personalised Medicine in Urologic Oncology
por: Borgmann, Hendrik, et al.
Publicado: (2021)

The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells
por: Hellsten, Rebecka, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r3n82l97rvrr7ulnj85rbbj8s9